{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:11Z","timestamp":1791357371820,"version":"4.3.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"22","license":[{"start":{"date-parts":[[2014,10,16]],"date-time":"2014-10-16T00:00:00Z","timestamp":1413417600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s00213-014-3764-2","type":"journal-article","created":{"date-parts":[[2014,10,15]],"date-time":"2014-10-15T00:16:29Z","timestamp":1413332189000},"page":"4255-4270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Antipsychotic-induced elevation of creatine kinase: a systematic review of the literature and recommendations for the clinical practice"],"prefix":"10.1007","volume":"231","author":[{"given":"Zacharias G.","family":"Laoutidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanellos T.","family":"Kioulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,16]]},"reference":[{"key":"3764_CR1","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1192\/bjp.158.5.706","volume":"158","author":"Adityanjee","year":"1991","unstructured":"Adityanjee (1991) The myth of elevated serum creatine phosphokinase level and neuroleptic malignant syndrome. Br J Psychiatry 158:706\u2013707","journal-title":"Br J Psychiatry"},{"issue":"3","key":"3764_CR2","doi-asserted-by":"crossref","first-page":"E49","DOI":"10.1176\/appi.neuropsych.23.3.E49","volume":"23","author":"S Agarkar","year":"2011","unstructured":"Agarkar S (2011) Elevated creatine kinase levels with second-generation antipsychotics. J Neuropsychiatry Clin Neurosci 23(3):E49\u2013E50. doi: 10.1176\/appi.neuropsych.23.3.E49","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"3764_CR3","volume-title":"Diagnostic and statistical manual of mental disorders: DSM-IV","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders: DSM-IV, 4th edn. American Psychiatric Association, Washington DC","edition":"4"},{"issue":"2","key":"3764_CR4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00213-005-0273-3","volume":"185","author":"S Apikoglu Rabus","year":"2006","unstructured":"Apikoglu Rabus S, Izzettin F, Rabus M, Bilici M (2006) Severe creatine kinase increase during quetiapine and mirtazapine treatment. Psychopharmacology (Berl) 185(2):263\u2013264","journal-title":"Psychopharmacology (Berl)"},{"key":"3764_CR5","doi-asserted-by":"crossref","unstructured":"Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Leucht S (2010) Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (11):CD006633. doi: 10.1002\/14651858.CD006633.pub2","DOI":"10.1002\/14651858.CD006633.pub2"},{"key":"3764_CR6","first-page":"CD006625","volume":"11","author":"L Asmal","year":"2013","unstructured":"Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S (2013) Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 11:CD006625. doi: 10.1002\/14651858.CD006625.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"3764_CR7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1055\/s-2005-837770","volume":"38","author":"U Baumgart","year":"2005","unstructured":"Baumgart U, Schmid R, Spiessl H (2005) Olanzapine-induced acute rhabdomyolysis\u2014a case report. Pharmacopsychiatry 38(1):36\u201337","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"3764_CR8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s002130000464","volume":"150","author":"E Boot","year":"2000","unstructured":"Boot E, de Haan L (2000) Massive increase in serum creatine kinase during olanzapine and quetiapine treatment, not during treatment with clozapine. Psychopharmacology (Berl) 150(3):347\u2013348","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"3764_CR9","first-page":"356","volume":"45","author":"JJ Cavanaugh","year":"1984","unstructured":"Cavanaugh JJ, Finlayson RE (1984) Rhabdomyolysis due to acute dystonic reaction to antipsychotic drugs. J Clin Psychiatry 45(8):356\u2013357","journal-title":"J Clin Psychiatry"},{"key":"3764_CR10","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ejim.2007.06.037","volume":"19","author":"YS Chatzizisis","year":"2008","unstructured":"Chatzizisis YS, Misirli G, Hatzitolios AI, Giannoglou GD (2008) The syndrome of rhabdomyolysis: complications and treatment. Eur J Intern Med 19:568\u2013574","journal-title":"Eur J Intern Med"},{"issue":"Suppl 8","key":"3764_CR11","first-page":"26","volume":"61","author":"RR Conley","year":"2000","unstructured":"Conley RR, Meltzer HY (2000) Adverse events related to olanzapine. J Clin Psychiatry 61(Suppl 8):26\u201329","journal-title":"J Clin Psychiatry"},{"issue":"12 Suppl 21","key":"3764_CR12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1017\/S1092852900015959","volume":"12","author":"CU Correll","year":"2007","unstructured":"Correll CU (2007) Acute and long-term adverse effects of antipsychotics. CNS Spectr 12(12 Suppl 21):10\u201314","journal-title":"CNS Spectr"},{"key":"3764_CR13","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.4088\/JCP.v67n1208","volume":"67","author":"M Hert De","year":"2006","unstructured":"De Hert M, Kalnicka D, van Winkel R, Wampers M, Hanssens L, van Eyck D, Scheen A, Peuschkens J (2006) Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 67:1889\u20131896","journal-title":"J Clin Psychiatry"},{"key":"3764_CR14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s002130000539","volume":"152","author":"S Deravajan","year":"2000","unstructured":"Deravajan S, Dursun SM (2000) Antipsychotic drugs, serum creatine kinase (CPK) and possible mechanisms. Psychopharmacology (Berl) 152:122","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"3764_CR15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/157488608784529251","volume":"3","author":"RJ Flanagan","year":"2008","unstructured":"Flanagan RJ (2008) Side effects of clozapine and some other psychoactive drugs. Curr Drug Saf 3(2):115\u2013122","journal-title":"Curr Drug Saf"},{"key":"3764_CR16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejim.2006.09.020","volume":"18","author":"GD Giannoglou","year":"2007","unstructured":"Giannoglou GD, Chatzizisis YS, Misirli G (2007) The syndrome of rhabdomyolysis: pathophysiology and diagnosis. Eur J Int Med 18:90\u2013100","journal-title":"Eur J Int Med"},{"issue":"2","key":"3764_CR17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1046\/j.1365-2796.2002.00936.x","volume":"251","author":"V Giner","year":"2002","unstructured":"Giner V, Mu\u00f1oz R, Red\u00f3n J (2002) Risperidone severe cerivastatin-induced rhabdomyolysis. J Intern Med 251(2):177\u2013178","journal-title":"J Intern Med"},{"key":"3764_CR18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/MOL.0b013e32825a6773","volume":"18","author":"CR Harper","year":"2007","unstructured":"Harper CR, Jacobson TA (2007) The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 18:401\u2013408","journal-title":"Curr Opin Lipidol"},{"issue":"6","key":"3764_CR19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/01.jcp.0000245560.21907.a4","volume":"26","author":"H Himmerich","year":"2006","unstructured":"Himmerich H, Ehrlinger M, Hackenberg M, L\u00f6hr B, Nickel T (2006) Possible case of quetiapine-induced rhabdomyolysis in a patient with depression treated with fluoxetine. J Clin Psychopharmacol 26(6):676\u2013677","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"3764_CR20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1046\/j.1442-2042.1999.06130.x","volume":"6","author":"S Hoshi","year":"1999","unstructured":"Hoshi S, Itoh A, Kato S, Suzuki K, Kawamura S, Orikasa S (1999) Severe rhabdomyolysis as a complication of high-dose chemotherapy in a patient with advanced testicular cancer. Int J Urol 6(1):56\u201358","journal-title":"Int J Urol"},{"key":"3764_CR21","author":"PR Karre","year":"2009","unstructured":"Karre PR, Gujral J, Rodriguez E (2009) Rhabdomyolysis with erratic serum creatinin phosphokinase levels: intramuscular injection of haloperidol decanoate. BMJ Case Rep. doi: 10.1136\/bcr.06.2009.1931","journal-title":"BMJ Case Rep"},{"issue":"1","key":"3764_CR22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1192\/bjp.164.1.118","volume":"164","author":"MS Keshavan","year":"1994","unstructured":"Keshavan MS, Stecker J, Kambhampati RK (1994) Creatine kinase elevations with clozapine. Br J Psychiatry 164(1):118\u2013120","journal-title":"Br J Psychiatry"},{"issue":"4","key":"3764_CR23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00004714-199508000-00011","volume":"15","author":"JI Kirson","year":"1995","unstructured":"Kirson JI, McQuistion HL, Pierce DW (1995) Severe elevations in serum creatine kinase associated with clozapine. J Clin Psychopharmacol 15(4):287\u2013288","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"3764_CR24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1055\/s-2006-931478","volume":"39","author":"JP Klein","year":"2006","unstructured":"Klein JP, Fiedler U, Appel H, Quante A, Jockers-Scher\u00fcbl MC (2006) Massive creatine kinase elevations with quetiapine: report of two cases. Pharmacopsychiatry 39(1):39\u201340","journal-title":"Pharmacopsychiatry"},{"key":"3764_CR25","author":"K Komossa","year":"2010","unstructured":"Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S (2010) Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. doi: 10.1002\/14651858.CD006654.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"3764_CR26","author":"K Komossa","year":"2011","unstructured":"Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S (2011) Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. doi: 10.1002\/14651858.CD006626.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"3764_CR27","first-page":"262","volume":"21","author":"W Koren","year":"1998","unstructured":"Koren W, Koren E, Nacasch N, Ehrenfeld M, Gur H (1998) Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium dependent potassium permeability of cell membranes. Clin Neuropharmacol 21(4):262\u2013264","journal-title":"Clin Neuropharmacol"},{"issue":"7","key":"3764_CR28","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1212\/WNL.35.7.1055","volume":"35","author":"AL Lazarus","year":"1985","unstructured":"Lazarus AL, Toglia JU (1985) Fatal myoglobinuric renal failure in a patient with tardive dyskinesia. Neurology 35(7):1055\u20131057","journal-title":"Neurology"},{"issue":"6","key":"3764_CR29","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1345\/aph.18282","volume":"33","author":"EL Marcus","year":"1999","unstructured":"Marcus EL, Vass A, Zislin J (1999) Marked elevation of serum creatine kinase associated with olanzapine therapy. Ann Pharmacother 33(6):697\u2013700","journal-title":"Ann Pharmacother"},{"issue":"7\u20138","key":"3764_CR30","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/106002809703100724","volume":"31","author":"MA Marinella","year":"1997","unstructured":"Marinella MA (1997) Rhabdomyolysis associated with haloperidol without evidence of NMS. Ann Pharmacother 31(7\u20138):927\u2013928","journal-title":"Ann Pharmacother"},{"issue":"4","key":"3764_CR31","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3109\/08860229509037611","volume":"17","author":"SJ Marsh","year":"1995","unstructured":"Marsh SJ, Dolson GM (1995) Rhabdomyolysis and acute renal failure during high-dose haloperidol therapy. Ren Fail 17(4):475\u2013478","journal-title":"Ren Fail"},{"issue":"4","key":"3764_CR32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4088\/JCP.v64n0420f","volume":"64","author":"E Mart\u00ed-Bonmat\u00ed","year":"2003","unstructured":"Mart\u00ed-Bonmat\u00ed E, San Valero-Carcel\u00e9n E, Ortega-Garc\u00eda MP, Rubini-Puig R (2003) Olanzapine elevation of serum creatine kinase. J Clin Psychiatry 64(4):483\u2013484","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"3764_CR33","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1016\/S0149-2918(03)80336-3","volume":"25","author":"PD Martin","year":"2003","unstructured":"Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, Lenz E (2003) Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 25(11):2822\u20132835","journal-title":"Clin Ther"},{"issue":"4","key":"3764_CR34","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1176\/appi.neuropsych.11110328","volume":"24","author":"E Marzetti","year":"2012","unstructured":"Marzetti E, Bocchino L, Teramo S, Scudieri G, Aulisa AG (2012) Rhabdomyolysis in a patient on aripiprazole with traumatic hip prosthesis luxation. J Neuropsychiatry Clin Neurosci 24(4):E40\u2013E41. doi: 10.1176\/appi.neuropsych.11110328","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"3764_CR35","author":"GM McMahon","year":"2013","unstructured":"McMahon GM, Zeng X, Walkar SS (2013) A risk prediction score for kidney failure or mortality in rhabdomyolysis. JAMA Intern Med. doi: 10.1001\/jamainternmed.2013.9774","journal-title":"JAMA Intern Med"},{"key":"3764_CR36","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1126\/science.159.3821.1368","volume":"159","author":"HY Meltzer","year":"1968","unstructured":"Meltzer HY (1968) Creatine kinase and aldolase in serum: abnormality common to acute psychoses. Science 159:1368\u20131370","journal-title":"Science"},{"key":"3764_CR37","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/archpsyc.1969.01740190104015","volume":"21","author":"HY Meltzer","year":"1969","unstructured":"Meltzer HY (1969) Muscle enzyme release in the acute psychoses. Arch Gen Psychiatry 21:102\u2013112","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"3764_CR38","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s002130000465","volume":"150","author":"HY Meltzer","year":"2000","unstructured":"Meltzer HY (2000) Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message? Psychopharmacology (Berl) 150(3):349\u2013350","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"3764_CR39","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0893-133X(95)00276-J","volume":"15","author":"HY Meltzer","year":"1996","unstructured":"Meltzer HY, Cola PA, Parsa M (1996) Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 15(4):395\u2013405","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"3764_CR40","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/070674370304800509","volume":"48","author":"WK Mohr","year":"2003","unstructured":"Mohr WK, Petti TA, Mohr BD (2003) Adverse effects associated with physical restraint. Can J Psychiatry 48(5):330\u2013337","journal-title":"Can J Psychiatry"},{"issue":"2","key":"3764_CR41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reaction. Clin Pharm Ther 30(2):239\u2013245","journal-title":"Clin Pharm Ther"},{"issue":"6","key":"3764_CR42","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1055\/s-2007-992158","volume":"40","author":"P Oulis","year":"2007","unstructured":"Oulis P, Koulouris GC, Konstantakopoulos G, Masdrakis VG (2007) Marked elevation of creatine kinase with sertindole: a case report. Pharmacopsychiatry 40(6):295\u2013296","journal-title":"Pharmacopsychiatry"},{"issue":"8","key":"3764_CR43","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1176\/ajp.145.8.1018","volume":"145","author":"C Pearlman","year":"1988","unstructured":"Pearlman C, Wheadon D, Epstein S (1988) Creatine kinase elevation after neuroleptic treatment. Am J Psychiatry 145(8):1018\u20131019","journal-title":"Am J Psychiatry"},{"issue":"2","key":"3764_CR44","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s00210-005-0004-7","volume":"372","author":"E Perlov","year":"2005","unstructured":"Perlov E, Tebartz van Elst L, Czygan M, Bubl E, Ebert D (2005) Serum creatine kinase elevation as a possible complication of therapy with olanzapine. Naunyn Schmiedebergs Arch Pharmacol 372(2):168\u2013169","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3764_CR45","author":"B Punukollu","year":"2008","unstructured":"Punukollu B, Rutherford H (2008) Serum creatine kinase elevation associated with olanzapine treatment. BMJ Case Rep. doi: 10.1136\/bcr.06.2008.0040","journal-title":"BMJ Case Rep"},{"issue":"5","key":"3764_CR46","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00002826-200009000-00007","volume":"23","author":"I Reznik","year":"2000","unstructured":"Reznik I, Volchek L, Mester R, Kotler M, Sarova-Pinhas I, Spivak B, Weizman A (2000) Myotoxicity and neurotoxicity during clozapine treatment. Clin Neuropharmacol 23(5):276\u2013280","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"3764_CR47","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/1752-1947-4-192","volume":"25","author":"F Robert","year":"2010","unstructured":"Robert F, Koenig M, Robert A, Boyer S, Cath\u00e9bras P, Camdessanch\u00e9 JP (2010) Acute camptocormia induced by olanzapine: a case report. J Med Case Rep 25(4):192. doi: 10.1186\/1752-1947-4-192","journal-title":"J Med Case Rep"},{"key":"3764_CR48","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1212\/WNL.47.6.1518","volume":"47","author":"SN Scelsa","year":"1996","unstructured":"Scelsa SN, Simpson DM, McQuistion HL, Fineman A, Ault K, Reichler B (1996) Clozapine induced myotoxicity in patients with chronic psychotic disorders. Neurology 47:1518\u20131523","journal-title":"Neurology"},{"issue":"1","key":"3764_CR49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1345\/aph.1R215","volume":"47","author":"EJ Scharman","year":"2013","unstructured":"Scharman EJ, Troutman WG (2013) Prevention of kidney injury following rhabdomyolysis: a systematic review. Ann Pharmacother 47(1):90\u2013105. doi: 10.1345\/aph.1R215","journal-title":"Ann Pharmacother"},{"key":"3764_CR50","doi-asserted-by":"crossref","unstructured":"Schennach-Wolff R, St\u00fcbner S, Riedel M, M\u00fcller N (2010) Extensive elevation of creatine kinase with generic clozapine, but not with Leponex. Psychiatry Res. 30;176(1):93. doi: 10.1016\/j.psychres.2009.03.014","DOI":"10.1016\/j.psychres.2009.03.014"},{"issue":"9","key":"3764_CR51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00152193-200030090-00034","volume":"30","author":"J Shuster","year":"2000","unstructured":"Shuster J (2000) Olanzapine and rhabdomyolysis. Nursing 30(9):87","journal-title":"Nursing"},{"issue":"4","key":"3764_CR52","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000026580","volume":"39","author":"T Terao","year":"1999","unstructured":"Terao T, Matsuda S, Kojima H, Okuno K, Hori H, Kaku A, Ueda N, Etoh A (1999) Incidence and risk factors of benign creatine phosphokinase elevations in chronic psychiatric patients. Neuropsychobiology 39(4):173\u2013180","journal-title":"Neuropsychobiology"},{"issue":"1","key":"3764_CR53","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00004714-198402000-00008","volume":"4","author":"ME Thase","year":"1984","unstructured":"Thase ME, Shostak M (1984) Rhabdomyolysis complicating rapid intramuscular neuroleptization. J Clin Psychopharmacol 4(1):46\u201348","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"3764_CR54","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0026-0495(97)90218-3","volume":"46","author":"PD Thompson","year":"1997","unstructured":"Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR (1997) Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 46(10):1206\u20131210","journal-title":"Metabolism"},{"issue":"4","key":"3764_CR55","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/JCP.0b013e3181accfc3","volume":"29","author":"KC Tseng","year":"2009","unstructured":"Tseng KC, Hwang TJ (2009) Rhabdomyolysis following dose increase of clozapine and combination therapy with lithium. J Clin Psychopharmacol 29(4):398\u2013399. doi: 10.1097\/JCP.0b013e3181accfc3","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"3764_CR56","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00228-009-0773-x","volume":"66","author":"F Ursini","year":"2010","unstructured":"Ursini F, Succurro E, Grembiale A, Arturi F (2010) Acute rhabdomyolysis during treatment with amisulpride and metformin. Eur J Clin Pharmacol 66(3):321\u2013322. doi: 10.1007\/s00228-009-0773-x","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"3764_CR57","first-page":"97","volume":"40","author":"J Velasco-Montes","year":"2012","unstructured":"Velasco-Montes J, Ori\u00f1uela-Gonz\u00e1lez I, Sanju\u00e1n-L\u00f3pez AZ (2012) Rhabdomyolysis secondary to quetiapine. Actas Esp Psiquiatr 40(2):97\u201399","journal-title":"Actas Esp Psiquiatr"},{"issue":"3","key":"3764_CR58","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/026988110401800316","volume":"18","author":"MA Webber","year":"2004","unstructured":"Webber MA, Mahmud W, Lightfoot JD, Shekhar A (2004) Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin. J Psychopharmacol 18(3):432\u2013434","journal-title":"J Psychopharmacol"},{"issue":"Suppl 21","key":"3764_CR59","first-page":"7","volume":"62","author":"DA Wirshing","year":"2001","unstructured":"Wirshing DA (2001) Adverse effects of atypical antipsychotics. J Clin Psychiatry 62(Suppl 21):7\u201310","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"3764_CR60","doi-asserted-by":"crossref","first-page":"E51","DOI":"10.1176\/appi.neuropsych.23.3.E51","volume":"23","author":"YF Wu","year":"2011","unstructured":"Wu YF, Chang KY (2011) Aripiprazole-associated rhabdomyolysis in a patient with schizophrenia. J Neuropsychiatry Clin Neurosci 23(3):E51. doi: 10.1176\/appi.neuropsych.23.3.E51","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"5","key":"3764_CR61","doi-asserted-by":"crossref","first-page":"835","DOI":"10.4088\/JCP.v67n0521a","volume":"67","author":"M Zink","year":"2006","unstructured":"Zink M, Knopf U, Argiriou S, Kuwilsky A (2006) A case of pulmonary thromboembolism and rhabdomyolysis during therapy with mirtazapine and risperidone. J Clin Psychiatry 67(5):835","journal-title":"J Clin Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-014-3764-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-014-3764-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-014-3764-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T01:55:55Z","timestamp":1565920555000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-014-3764-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,16]]},"references-count":61,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["3764"],"URL":"https:\/\/doi.org\/10.1007\/s00213-014-3764-2","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,16]]}}}